Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Standard Dose
75MG;75MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 207315 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 75MG;75MG Sponsor HETERO LABS LTD III Submission history Latest submission status date: 2017-05-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 207315 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 75MG;75MG Sponsor HETERO LABS LTD III Submission history Latest submission status date: 2017-05-05 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.